M. Kulke

457 total citations
13 papers, 350 citations indexed

About

M. Kulke is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, M. Kulke has authored 13 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Epidemiology and 4 papers in Neurology. Recurrent topics in M. Kulke's work include Neuroendocrine Tumor Research Advances (6 papers), Neuroblastoma Research and Treatments (4 papers) and Lung Cancer Research Studies (4 papers). M. Kulke is often cited by papers focused on Neuroendocrine Tumor Research Advances (6 papers), Neuroblastoma Research and Treatments (4 papers) and Lung Cancer Research Studies (4 papers). M. Kulke collaborates with scholars based in United States, Canada and Sweden. M. Kulke's co-authors include David P. Ryan, Charles S. Fuchs, Keith Stuart, Geoffrey Liu, David C. Christiani, Kofi Asomaning, Rebecca S. Heist, Li Su, Craig C. Earle and James C. Yao and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

M. Kulke

13 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Kulke United States 8 182 126 116 86 85 13 350
P. Bonomi United States 9 212 1.2× 88 0.7× 82 0.7× 39 0.5× 53 0.6× 26 337
Manoj Shah India 11 163 0.9× 42 0.3× 121 1.0× 65 0.8× 37 0.4× 29 346
Mark Karwal United States 9 147 0.8× 114 0.9× 61 0.5× 41 0.5× 57 0.7× 26 330
Yingwei Pan China 8 135 0.7× 70 0.6× 150 1.3× 102 1.2× 21 0.2× 14 393
Maribel Mármol Spain 8 175 1.0× 65 0.5× 90 0.8× 82 1.0× 48 0.6× 8 278
J-F Fléjou France 7 266 1.5× 198 1.6× 125 1.1× 76 0.9× 120 1.4× 7 491
Paola Mattiolo Italy 12 311 1.7× 114 0.9× 66 0.6× 124 1.4× 35 0.4× 29 396
Omar Kayaleh United States 8 301 1.7× 63 0.5× 162 1.4× 73 0.8× 26 0.3× 15 457
F. Bacci Italy 7 102 0.6× 34 0.3× 50 0.4× 31 0.4× 22 0.3× 14 244
Thomas Hendrik Knocke Austria 9 69 0.4× 50 0.4× 85 0.7× 118 1.4× 11 0.1× 12 364

Countries citing papers authored by M. Kulke

Since Specialization
Citations

This map shows the geographic impact of M. Kulke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Kulke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Kulke more than expected).

Fields of papers citing papers by M. Kulke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Kulke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Kulke. The network helps show where M. Kulke may publish in the future.

Co-authorship network of co-authors of M. Kulke

This figure shows the co-authorship network connecting the top 25 collaborators of M. Kulke. A scholar is included among the top collaborators of M. Kulke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Kulke. M. Kulke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Wolin, Edward M., Beth Chasen, M. Kulke, et al.. (2017). NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors. Neuroendocrinology. 105. 257–257. 2 indexed citations
2.
Lapuerta, Pablo, M. Kulke, Martyn Caplin, et al.. (2017). Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl. Annals of Oncology. 28. v147–v148. 1 indexed citations
3.
Khoury, Hanane, Brock O’Neil, Luc Lavoie, et al.. (2016). To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis. Value in Health. 19(7). A385–A386. 1 indexed citations
4.
Zhai, Rihong, Yongyue Wei, Li Su, et al.. (2014). Whole-miRNome profiling identifies prognostic serum miRNAs in esophageal adenocarcinoma: the influence of Helicobacter pylori infection status. Carcinogenesis. 36(1). 87–93. 19 indexed citations
5.
Walsh, Kyle M., Murim Choi, Kjell Öberg, et al.. (2010). A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocrine Related Cancer. 18(1). 171–180. 19 indexed citations
6.
Phan, Alexandria T., James C. Yao, David R. Fogelman, et al.. (2010). A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).. Journal of Clinical Oncology. 28(15_suppl). 4001–4001. 62 indexed citations
7.
Bradbury, Penelope A., Rihong Zhai, M. Kulke, et al.. (2009). Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 30(5). 793–798. 47 indexed citations
8.
Cheung, Winson Y., Rihong Zhai, M. Kulke, et al.. (2009). Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis. 30(8). 1363–1367. 12 indexed citations
9.
Liu, Geoffrey, Kofi Asomaning, Li Su, et al.. (2008). Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 29(12). 2330–2334. 55 indexed citations
10.
Kulke, M., Heinz‐Josef Lenz, Neal J. Meropol, et al.. (2005). A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). Journal of Clinical Oncology. 23(16_suppl). 4008–4008. 57 indexed citations
11.
Enzinger, Peter C., Joseph I. Clark, David P. Ryan, et al.. (2004). Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. Journal of Clinical Oncology. 22(14_suppl). 4040–4040. 1 indexed citations
12.
Enzinger, Peter C., Jeffrey W. Clark, David P. Ryan, et al.. (2004). Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. Journal of Clinical Oncology. 22(14_suppl). 4040–4040. 6 indexed citations
13.
Fuchs, Charles S., Jeffrey W. Clark, David P. Ryan, et al.. (2002). A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 94(12). 3186–3191. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Bonomi Breakdown of academic impact, for papers by Manoj Shah Breakdown of academic impact, for papers by Mark Karwal Breakdown of academic impact, for papers by Yingwei Pan Breakdown of academic impact, for papers by Maribel Mármol Breakdown of academic impact, for papers by J-F Fléjou Breakdown of academic impact, for papers by Paola Mattiolo Breakdown of academic impact, for papers by Omar Kayaleh Breakdown of academic impact, for papers by F. Bacci Breakdown of academic impact, for papers by Thomas Hendrik Knocke
Rankless by CCL
2026